Gastric Cancer
Dr. Rodón Ahnert compares the differences of sacituzumab tirumotecan use in the second- vs third-line setting for patients.
Pembrolizumab Shows Promise as a First-line Treatment for Advanced Gastric, Gastroesophageal Cancers
The final results from the KEYNOTE-811 trial will determine if Keytruda will receive continued approval from the FDA.
HERCESSI was developed by Accord BioPharma, Inc., the US specialty division of Intas Pharmaceuticals Ltd.
Surgical resection with curative intent is the primary therapy for gastric cancer, yet the 5-year survival rate is just 20%.
Patients with a DpR of ≥30% had a favorable survival time with nivolumab monotherapy as a later-line treatment.
For those with a PD-L1 CPS of 5 or higher who received the combination therapy, the median OS was not achieved.
Researchers investigated the potential of an anti-H Pylori treatment after radical gastrectomy to improve survival.
Individuals with MLH1, MSH2, and EpCAM PVs were found to have a higher risk of developing GC and DC at the age of 70 years.
Dr. Janjigian discusses how the agent - created with invariant natural killer t-cells - works in tandem with other therapies.
Dr. Janjigian describes the history behind nivolumab treatment, and the differences in initial results versus follow-up.
Advertisement
Expert Interviews on GI Oncology
Advertisement
Advertisement
Section Editor
Nataliya Uboha, MD, PhDGastrointestinal Medical Oncologist | University of Wisconsin School of Medicine and Public Health
Advertisement
Latest GI Oncology News
